StockData
Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc. (FLGT) stock

FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)

Close on Nov 17, 2026Market cap $666.15MP/E –Yield –

Earnings

Fulgent Genetics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 26, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$90.40M
+7.5% on a year earlier
Non-GAAP loss per share, Q3 FY2026
-$0.09
$0.14 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Fulgent Genetics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 26, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$90.40M+7.5%-$0.48-$0.09Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026during market hours$85.40M+4.4%-$1.05-$0.58Release
Q1 FY2026ended Mar 31, 2026May 1, 2026before the open$71.10M-3.3%-$0.80-$0.36Release
Q4 FY2025ended Dec 31, 2025Feb 27, 2026before the open$83.30M+9.3%-$0.76$0.16Release
Q3 FY2025ended Sep 30, 2025Nov 7, 2025before the open$84.07M+17.3%-$0.21$0.14Release
Q2 FY2025ended Jun 30, 2025Aug 1, 2025before the open$81.80M+15.2%-$0.62$0.07Release
Q1 FY2025ended Mar 31, 2025May 2, 2025before the open$73.50M+14.0%-$0.37$0.04Release
Q4 FY2024ended Dec 31, 2024Feb 28, 2025before the open$76.20M+8.1%-$0.19$0.04Release
Q3 FY2024ended Sep 30, 2024Nov 8, 2024before the open$71.70M-15.6%-$0.48$0.31Release
Q2 FY2024ended Jun 30, 2024Aug 2, 2024before the open$71.00M+4.4%-$0.29$0.15Release
Q1 FY2024ended Mar 31, 2024May 3, 2024before the open$64.50M-2.6%$0.45$0.01Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Fulgent Genetics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY2026$330.00M – $340.00M–NewNov 5, 2026
RevenueFY2026$330.00M – $340.00M$350.00MLoweredJul 30, 2026
Non-GAAP loss per sharenon-GAAPFY2026$1.65 – $1.75–NewNov 5, 2026
Non-GAAP loss per sharenon-GAAPFY2026-$2.35 – -$2.22-$1.59LoweredJul 30, 2026
Cash, cash equivalents, restricted cash, and investments in marketable securitiesFY2026$630.00M–NewNov 5, 2026
Cash, cash equivalents, restricted cash, and investments in marketable securitiesFY2026$610.00M$636.00MLoweredJul 30, 2026
Non-GAAP lossnon-GAAPFY2026$46.00M – $50.00M–NewNov 5, 2026
Non-GAAP lossnon-GAAPFY2026-$67.00M – -$63.00M-$46.00MLoweredJul 30, 2026

Guidance vs results

The last range Fulgent Genetics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025EPS (GAAP)-$1.70-$1.96Σ4QBelow range
FY2025Non-GAAP income per share$0.30$0.41Σ4QAbove range
FY2025Revenue$325.00M$322.67MΣ4QBelow range
Q3 FY2023Revenue$65.00M$85.00MAbove range
Q2 FY2023Revenue$62.00M$68.00MAbove range
Q1 FY2023Revenue$56.00M$66.20MAbove range
Q4 FY2022Revenue$60.00M$67.70MAbove range
Q3 FY2022Revenue$105.00M$105.70MAbove range
Q2 FY2022Revenue$125.00M$125.30MAbove range
Q1 FY2022Revenue$245.00M$320.30MAbove range
Q4 FY2021Revenue$189.00M$251.70MAbove range

Guidance history

Every forecast Fulgent Genetics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Non-GAAP loss per shareFY2026$1.65 – $1.75New
Nov 5, 2026Cash, cash equivalents, restricted cash, and investments in marketable securitiesFY2026$630.00MNew
Nov 5, 2026Non-GAAP lossFY2026$46.00M – $50.00MNew
Nov 5, 2026RevenueFY2026$330.00M – $340.00MNew
Jul 30, 2026Non-GAAP loss per shareFY2026-$2.35 – -$2.22Lowered
Jul 30, 2026Non-GAAP lossFY2026-$67.00M – -$63.00MLowered
Jul 30, 2026Cash, cash equivalents, restricted cash, and investments in marketable securitiesFY2026$610.00MLowered
Jul 30, 2026RevenueFY2026$330.00M – $340.00MLowered
May 1, 2026Non-GAAP loss per shareFY2026-$1.59Lowered
May 1, 2026Non-GAAP lossFY2026-$46.00MNew
May 1, 2026Cash, cash equivalents, restricted cash, and investments in marketable securitiesFY2026$636.00MLowered
May 1, 2026RevenueFY2026$350.00MReaffirmed
Feb 27, 2026Non-GAAP lossFY2026-$1.45New
Feb 27, 2026Cash, cash equivalents, restricted cash, and investments in marketable securitiesFY2026$685.00MNew
Feb 27, 2026RevenueFY2026$350.00MNew
Nov 7, 2025Non-GAAP income per shareFY2025$0.30New
Nov 7, 2025GAAP loss per shareFY2025-$1.70New
Nov 7, 2025RevenueFY2025$325.00MNew
Aug 1, 2025Non-GAAP loss per shareFY2025-$0.35Raised
Aug 1, 2025GAAP loss per shareFY2025-$2.10Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Fulgent Genetics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. News
  6. News
  7. Results
  8. Results
  9. Update
  10. Results
  11. Results
  12. News
  13. Results
  14. Results
  15. News

See a number that looks wrong?